Valuation: Inhalation Sciences Sweden AB

Market Cap 7.83M 820K 711K 666K 607K 1.14M 78.25M 1.16M 3.06M 39.18M 3.08M 3.01M 131M P/E 2024
-12.8x
P/E 2025 -12.4x
Enterprise Value 5M 524K 454K 425K 388K 729K 49.97M 741K 1.96M 25.02M 1.97M 1.92M 83.43M EV / Sales 2024
5.6x
EV / Sales 2025 55x
Free-Float
94.25%
Yield 2024 *
-
Yield 2025 -
1 day-8.38%
1 week-17.30%
Current month-15.00%
1 month-31.39%
3 months-44.36%
6 months-50.32%
Current year-96.47%
1 week 0.14
Extreme 0.145
0.18
1 month 0.14
Extreme 0.145
0.24
Current year 0.14
Extreme 0.145
0.58
1 year 0.14
Extreme 0.145
0.58
3 years 0.14
Extreme 0.145
4.99
5 years 0.14
Extreme 0.145
11.3
10 years 0.14
Extreme 0.145
15.48
Manager TitleAgeSince
Chief Executive Officer - 2019-09-15
Chief Tech/Sci/R&D Officer - 2004-12-31
Corporate Officer/Principal - 2025-06-01
Director TitleAgeSince
Director/Board Member - 2004-12-31
Director/Board Member - 2022-08-31
Director/Board Member - 2024-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-8.38%-17.30%-96.47%-94.67% 899K
-0.33%+4.36%+26.31%+10.89% 224B
-0.80%+3.07%+0.03%-19.43% 146B
+0.01%+6.95%-16.09%+31.78% 142B
+0.45%+7.71%-49.90%+0.76% 74.19B
-0.65%+4.59%+20.95%+17.18% 53.99B
-1.41%-0.54%-15.65%-17.29% 50.85B
-0.84%+5.05%+26.36%+16.85% 42.22B
+0.28%+4.04%+45.75%+42.68% 40.75B
-0.65%+2.90%-2.86%+0.96% 32.86B
Average -1.23%+2.28%-6.16%-1.03% 80.61B
Weighted average by Cap. -0.37%+4.55%+3.88%+8.31%

Financials

2024 2025
Net sales 11.05M 1.16M 1M 939K 857K 1.61M 110M 1.64M 4.32M 55.26M 4.34M 4.25M 184M 3.04M 319K 276K 259K 236K 443K 30.38M 450K 1.19M 15.21M 1.2M 1.17M 50.72M
Net income -5.15M -539K -467K -438K -399K -750K -51.42M -762K -2.01M -25.75M -2.02M -1.98M -85.85M -10.16M -1.06M -922K -864K -788K -1.48M -101M -1.5M -3.97M -50.82M -4M -3.91M -169M
Net Debt -4M -419K -363K -340K -310K -584K -39.99M -593K -1.56M -20.02M -1.57M -1.54M -66.77M -2.83M -297K -257K -241K -220K -413K -28.28M -419K -1.11M -14.16M -1.11M -1.09M -47.22M
Logo Inhalation Sciences Sweden AB
Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Company’s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Company’s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Company’s main shareholder is Nordnet Pensionsforsakring.
Employees
5
Date Price Change Volume
26-08-12 SEK 0.1530 -8.38% 669,703
26-08-11 SEK 0.1670 -6.18% 470,995
26-08-10 SEK 0.1780 0.00% 102,793
26-08-07 SEK 0.1780 -1.39% 6,146
26-08-06 SEK 0.1805 -2.43% 5,702

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISAB Stock